Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Published December 10, 2018
Citation Information: J Clin Invest. 2019;129(1):349-363. https://doi.org/10.1172/JCI123391.
View: Text | PDF
Research Article Immunology Oncology Article has an altmetric score of 25

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

  • Text
  • PDF
Abstract

While immune checkpoint blockade leads to potent antitumor efficacy, it also leads to immune-related adverse events in cancer patients. These toxicities stem from systemic immune activation resulting in inflammation of multiple organs, including the gastrointestinal tract, lung, and endocrine organs. We developed a dual variable domain immunoglobulin of anti-CTLA4 antibody (anti-CTLA4 DVD, where CTLA4 is defined as cytotoxic T lymphocyte–associated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield the inner anti-CTLA4–binding domain. Upon reaching the tumor, the outer domain was cleaved by membrane type-serine protease 1 (MT-SP1) present in the tumor microenvironment, leading to enhanced localization of CTLA4 blockade. Anti-CTLA4 DVD markedly reduced multiorgan immune toxicity by preserving tissue-resident Tregs in Rag 1–/– mice that received naive donor CD4+ T cells from WT C57BL/6j mice. Moreover, anti-CTLA4 DVD induced potent antitumor effects by decreasing tumor-infiltrating Tregs and increasing the infiltration of antigen-specific CD8+ T lymphocytes in TRAMP-C2–bearing C57BL/6j mice. Treg depletion was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanism, as anti-CTLA4 without the FcγR-binding portion (anti-CTLA4 DANA) spared Tregs, preventing treatment-induced toxicities. In summary, our results demonstrate an approach to anti-CTLA4 blockade that depletes tumor-infiltrating, but not tissue-resident, Tregs, preserving antitumor effects while minimizing toxicity. Thus, our tumor-conditional anti-CTLA4 DVD provides an avenue for uncoupling antitumor efficacy from immunotherapy-induced toxicities.

Authors

Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, Michael Evans, Junnian Wei, Yung-hua Wang, Mingyi Chen, John Huang, Chanhyuk Park, Anthony Chang, Jiaxi Wang, Susan Westmoreland, Christine Beam, Dave Banach, Diana Bowley, Feng Dong, Jane Seagal, Wendy Ritacco, Paul L. Richardson, Soumya Mitra, Grace Lynch, Pete Bousquet, John Mankovich, Gillian Kingsbury, Lawrence Fong

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2009 Total
Citations: 2 9 11 25 11 13 4 1 1 77
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2022 (25)

Title and authors Publication Year
Aging-associated and CD4 T cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events
Hirotake Tsukamoto, Yoshihiro Komohara, Yusuke Tomita, Yuji Miura, Takanobu Motoshima, Kosuke Imamura, Toshiki Kimura, Tokunori Ikeda, Tomomi Kamba, Takuro Sakagami, Hiroyuki Oshiumi
Proceedings of the National Academy of Sciences 2022
Role of Serine Proteases at the Tumor-Stroma Interface
R Tagirasa, E Yoo
Frontiers in immunology 2022
Determining the Prognostic Value of Spliceosome-Related Genes in Hepatocellular Carcinoma Patients
J Liu, L Gu, D Zhang, W Li
Frontiers in Molecular Biosciences 2022
SIRT7 is a Prognostic Biomarker in Kidney Renal Clear Cell Carcinoma That is Correlated with Immune Cell Infiltration
W Zhang, Y Qian, X Jin, Y Wang, L Mu, Z Jiang
International journal of general medicine 2022
Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy
X Qi, Q Li, X Che, Q Wang, G Wu
Frontiers in immunology 2022
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
D Xue, B Moon, J Liao, J Guo, Z Zou, Y Han, S Cao, Y Wang, Y Fu, H Peng
Science Immunology 2022
Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma.
Wang H, Fu Y, Da BB, Xiong G
Journal of Healthcare Engineering 2022
Immunotherapy: Reshape the Tumor Immune Microenvironment.
Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C
Frontiers in immunology 2022
Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma
Yang H, Lei G, Sun F, Cheng J, Yan J, Zhang S, Yang P
Frontiers in Oncology 2022
Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch KG, Benz J, Ehler A, Lauer ME, Ringler P, Kobold S, Endres S, Klein C, Brinkmann U
Biological Chemistry 2022
Exploiting protease activation for therapy
Bleuez C, Koch WF, Urbach C, Hollfelder F, Jermutus L
Drug Discovery Today 2022
Mechanistic insights into the rational design of masked antibodies
Orozco CT, Bersellini M, Irving LM, Howard WW, Hargreaves D, Devine PW, Siouve E, Browne GJ, Bond NJ, Phillips JJ, Ravn P, Jackson SE
mAbs 2022
A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma
Liu J, Yin J, Wang Y, Cai L, Geng R, Du M, Zhong Z, Ni S, Huang X, Yu H, Bai J
Biological Procedures Online 2022
An immune-related gene prognostic risk index for pancreatic adenocarcinoma
Su Y, Qi R, Li L, Wang X, Li S, Zhao X, Hou R, Ma W, Liu D, Zheng J, Shi M
Frontiers in immunology 2022
A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer
Wang H, Liu J, Yang J, Wang Z, Zhang Z, Peng J, Wang Y, Hong L
Frontiers in immunology 2022
A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT
Fei L, Lu Z, Xu Y, Hou G
Frontiers in Genetics 2022
CTLA4-Linked Autoimmunity in the Pathogenesis of Endometriosis and Related Infertility: A Systematic Review.
Mikuš M, Goldštajn MŠ, Brlečić I, Dumančić S, Laganà AS, Chiantera V, Vujić G, Ćorić M
International journal of molecular sciences 2022
Comprehensive analysis of SLC43A2 on the tumor immune microenvironment and prognosis of liver hepatocellular carcinoma
Liao Y, Weng J, Chen L, Hu N, Yuan X, Wang J, He F, Cai Y, Huang Q, Wang J, Huang L
Frontiers in Genetics 2022
Construction of a competing endogenous RNA network in head and neck squamous cell carcinoma by pan-cancer analysis
Zheng D, Luo S, Wang S, Huang J, Zhou Y, Su L, Chen Z, Wang S, He W
Translational cancer research 2022
A CD8+ T cell-associated immune gene panel for prediction of the prognosis and immunotherapeutic effect of melanoma
Sun S, Zhi Z, Su Y, Sun J, Li Q
Frontiers in immunology 2022
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Wei J, Yang Y, Wang G, Liu M
Frontiers in immunology 2022
Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
Safaeifard F, Goliaei B, Aref AR, Foroughmand-Araabi MH, Goliaei S, Lorch J, Jenkins RW, Barbie DA, Shariatpanahi SP, Rüegg C
Cells 2022
Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy
Yan Y, Feng X, Li C, Lerut T, Li H
Chinese Medical Journal 2022
FOXP3+ regulatory T cells and the immune escape in solid tumours
Qiu Y, Ke S, Chen J, Qin Z, Zhang W, Yuan Y, Meng D, Zhao G, Wu K, Li B, Li D
Frontiers in immunology 2022
Identification and Verification of an Alternative Polyadenylation-Related lncRNA Prognostic Signature for Glioma.
Wang H, Jiang Z
Computational and mathematical methods in medicine 2022

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 21 X users
Referenced in 2 patents
On 3 Facebook pages
109 readers on Mendeley
See more details